Pharma Mar Earnings Estimate

Pharma Mar Earnings per Share Projection vs Actual

About Pharma Mar Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Pharma Mar earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Pharma Mar estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Pharma Mar fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company was incorporated in 1986 and is based in Madrid, Spain. Pharma Mar operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 477 people.

Currently Active Assets on Macroaxis

Other Information on Investing in Pharma Pink Sheet

Pharma Mar financial ratios help investors to determine whether Pharma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharma with respect to the benefits of owning Pharma Mar security.